Literature DB >> 11879135

Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis.

Nicholas E Engelbrecht1, Thomas M Aaberg, Jennie Sung, Mary Lou Lewis.   

Abstract

OBJECTIVE: To report the visual outcome in patients with a neovascular membrane (NVM) associated with idiopathic juxtafoveolar telangiectasis (IJFT).
METHODS: We performed a retrospective, noncomparative analysis of 26 eyes of 16 patients with an NVM associated with bilateral IJFT (Gass classification group 2A). Eyes were divided into 2 groups: group WO (n = 11) included eyes with IJFT without evidence of an NVM on initial examination; eyes in group W (n = 15) had an NVM at the initial diagnosis of IJFT. In group WO, the initial visual acuity and the time between the initial examination to the diagnosis of an NVM were evaluated. Characteristic fundus findings, including the presence or absence of a chorioretinal anastomosis, intraretinal pigmentary plaques, and crystalline deposits, as well as the final visual acuity were reviewed for both groups.
RESULTS: The initial visual acuity for eyes in group WO ranged from 20/20 to 20/70 (median, 20/30); in group W, from 20/20 to 4/200 (median, 20/70). The average time from initial diagnosis of IJFT to the development of an NVM was 73 months (range, 5-142 months). In group WO, chorioretinal anastomosis and concurrent perivascular retinal pigment epithelial hyperplasia were observed before the development of an NVM. The final visual acuity for all eyes ranged from 20/40 to 2/200 (median, 20/200). Eighty-one percent of eyes (21/26) had a final visual acuity of 20/200 or worse.
CONCLUSIONS: The stable final visual acuity in patients with an NVM associated with IJFT is generally poor, with 80% of eyes in this series having a final visual acuity of l20/200 or worse. In patients with IJFT, the presence of a chorioretinal anastomosis and retinal pigment epithelial hyperplastic plaques always preceded the development of an NVM.

Entities:  

Mesh:

Year:  2002        PMID: 11879135     DOI: 10.1001/archopht.120.3.320

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  17 in total

1.  Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia.

Authors:  Lazaros Konstantinidis; Irmela Mantel; Leonidas Zografos; Aude Ambresin
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-11       Impact factor: 3.117

2.  Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia.

Authors:  Teresa Barth; Florian Zeman; Horst Helbig; Maria-Andreea Gamulescu
Journal:  Int Ophthalmol       Date:  2017-01-21       Impact factor: 2.031

3.  Subretinal neovascular membrane associated with type 2a idiopathic juxtafoveolar telangiectasis in pseudoxanthoma elasticum.

Authors:  Maurizio Battaglia Parodi; Pierluigi Iacono; Giuseppe Ravalico
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-09-19       Impact factor: 3.117

4.  Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.

Authors:  Rodrigo Jorge; Rogério A Costa; Daniela Calucci; Ingrid U Scott
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-29       Impact factor: 3.117

5.  Retinal vascular density evaluated by optical coherence tomography angiography in macular telangiectasia type 2.

Authors:  Berna Dogan; Muhammet Kazim Erol; Melih Akidan; Elcin Suren; Yusuf Akar
Journal:  Int Ophthalmol       Date:  2019-01-03       Impact factor: 2.031

6.  Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors:  Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal:  Middle East Afr J Ophthalmol       Date:  2010-07

Review 7.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

8.  Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia.

Authors:  Pukhraj Rishi; Daraius Shroff; Ekta Rishi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-01-12       Impact factor: 3.117

9.  [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Authors:  F G Holz; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

10.  A case of subretinal neovascularization treated with intravitreal ranibizumab in a patient with idiopathic juxtafoveal retinal telangiectasis.

Authors:  Dimitrios Karagiannis; Ilias Georgalas; Ioannis Ladas; Parikakis Eustratios; Panagiotis Mitropoulos
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.